ElectroCore's Stock Is Trading Higher As nVNS Decreases Certain COVID-19-Associated Biomarkers

ElectroCore Inc ECOR has announced top-line results from the SAVIOR-1 study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire in hospitalized COVID-19 patients.
The investigator-initiated trial conducted in Spain was designed to evaluate the safety and feasibility of nVNS in addition to the current standard of care.
Patients' clinical and biochemical endpoints were measured over the first five days of therapy, and the adjusted means were compared.
It was noted that the assessment of the severity of the condition resulted in a 3.5 to 1 bias with more severe patients in the treatment arm.
Concerning the clinical endpoint of oxygen saturation, the nVNS treated group showed a modest but no significant improvement.
Among the biomarkers evaluated, the adjusted mean decrease in C-Reactive Protein (CRP) from baseline was significantly greater in the nVNS treated group (-59.08 vs. -27.83).
Trends toward significance were also observed for decreases in the treatment group for procalcitonin (-0.11 vs. -0.05) and d-dimer (-277.53 vs. 1264.37).
Increased CRP levels, procalcitonin, and d-dimer have all been reported to be associated with more severe disease.
Other biochemical measures also favored the treatment group but did not achieve significance.
nVNS was well tolerated with no major device-related adverse events, and the therapy was administered three times daily on the majority of patients as outlined in the study protocol.
Full data from the study, including cytokine levels pending final lab results, will be submitted to a peer-reviewed journal later this year.
Price Action: ECOR shares are up 8.67% at $2.13 in the premarket trading on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments